Failure of empirical systemic antifungal therapy in mechanically ventilated critically ill patients

Area of Science:

• Critical Care Medicine
• Infectious Diseases
• Clinical Epidemiology

Background:

• Systemic antifungal treatments are frequently given empirically to critically ill patients, even without confirmed invasive fungal infections.
• The decision to treat is often based on clinical suspicion rather than definitive evidence.

Purpose of the Study:

• To evaluate the impact of empirical systemic antifungal treatment on 30-day survival in critically ill patients with suspected invasive candidiasis.
• To assess the association between antifungal therapy and mortality or the development of invasive candidiasis.

Main Methods:

• A causal model for longitudinal data was employed to analyze outcomes in nonneutropenic, non-transplant intensive care unit patients intubated for at least 5 days.
• Patients were assessed for a composite endpoint of hospital mortality or documented invasive candidiasis within 30 days.
• Adjustments were made for baseline and time-dependent confounders, including illness severity and Candida colonization.

Main Results:

• Out of 1,491 patients, 100 received empirical antifungal treatment; these patients were generally more severely ill.
• No significant association was found between antifungal treatment and a reduced risk of mortality or invasive candidiasis (HR, 1.05; 95% CI, 0.56-1.96).
• The study found no statistically significant benefit of empirical antifungal therapy on the primary composite endpoint.

Conclusions:

• Empirical systemic antifungal therapy did not demonstrate outcome benefits in the studied population of critically ill, nonneutropenic, non-transplanted patients.
• The study lacked sufficient power to rule out a treatment effect in specific subgroups.
• Further research is recommended to identify reliable surrogate markers for guiding empirical antifungal treatment decisions in invasive candidiasis.